76 related articles for article (PubMed ID: 30134149)
1. VEGF165b mutant with a prolonged half-life and enhanced anti-tumor potency in a mouse model.
Zhang H; Jia E; Xia W; Lu C; Zhu W
J Biotechnol; 2018 Oct; 284():84-90. PubMed ID: 30134149
[TBL] [Abstract][Full Text] [Related]
2. Expression and purification of recombinant human serum albumin fusion protein with VEGF165b in Pichia pastoris.
Zhu RY; Xin X; Dai HY; Li Q; Lei JY; Chen Y; Jin J
Protein Expr Purif; 2012 Sep; 85(1):32-7. PubMed ID: 22750397
[TBL] [Abstract][Full Text] [Related]
3. VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.
Ganta VC; Choi M; Kutateladze A; Annex BH
Circ Res; 2017 Jan; 120(2):282-295. PubMed ID: 27974423
[TBL] [Abstract][Full Text] [Related]
4. Systems Pharmacology of VEGF165b in Peripheral Artery Disease.
Clegg LE; Ganta VC; Annex BH; Mac Gabhann F
CPT Pharmacometrics Syst Pharmacol; 2017 Dec; 6(12):833-844. PubMed ID: 29193887
[TBL] [Abstract][Full Text] [Related]
5. A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF
Chu LH; Ganta VC; Choi MH; Chen G; Finley SD; Annex BH; Popel AS
Sci Rep; 2016 Nov; 6():37030. PubMed ID: 27853189
[TBL] [Abstract][Full Text] [Related]
6. Generation of a chimeric plasmin-resistant VEGF165/VEGF183 (132-158) protein and its comparative activity.
Huiyong Z; Yong L; Yunxiao S; Wuling Z; Jingjing L; Taiming L
Protein Pept Lett; 2013 Aug; 20(8):947-54. PubMed ID: 23469806
[TBL] [Abstract][Full Text] [Related]
7. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y
Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
9. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
10. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.
Rennel E; Waine E; Guan H; Schüler Y; Leenders W; Woolard J; Sugiono M; Gillatt D; Kleinerman E; Bates D; Harper S
Br J Cancer; 2008 Apr; 98(7):1250-7. PubMed ID: 18349828
[TBL] [Abstract][Full Text] [Related]
11. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
12. VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway.
Wang X; Liang C; Xia W; Guo C; Niu Z; Zhu W; Zhang H
Mol Immunol; 2020 Dec; 128():41-46. PubMed ID: 33068832
[TBL] [Abstract][Full Text] [Related]
13. The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells.
Wang S; Cai R; Ma J; Liu T; Ke X; Lu H; Fu J
Phytomedicine; 2015 Oct; 22(11):1017-26. PubMed ID: 26407944
[TBL] [Abstract][Full Text] [Related]
14. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
15. VEGF165b Mutant Promotes the Apoptosis of Murine Breast Cancer Cells Induced by Paclitaxel by Inducing Tumor Vessel Maturation.
Liang C; Li Y; Guo E; Bai S; Wang Y; Zhang H
Protein Pept Lett; 2023; 30(11):951-958. PubMed ID: 37861033
[TBL] [Abstract][Full Text] [Related]
16. VEGF isoforms have differential effects on permeability of human pulmonary microvascular endothelial cells.
Ourradi K; Blythe T; Jarrett C; Barratt SL; Welsh GI; Millar AB
Respir Res; 2017 Jun; 18(1):116. PubMed ID: 28578669
[TBL] [Abstract][Full Text] [Related]
17. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological implications of vascular endothelial growth factor 165b expression in oral squamous cell carcinoma stroma.
Nagasaki M; Kondo S; Mukudai Y; Kamatani T; Akizuki A; Yaso A; Shimane T; Shirota T
Oncol Rep; 2016 Jul; 36(1):573-81. PubMed ID: 27221145
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased
Feng J; Zhao C; Wang L; Qu L; Zhu H; Yang Z; An G; Tian H; Shou C
Theranostics; 2018; 8(8):2094-2106. PubMed ID: 29721065
[TBL] [Abstract][Full Text] [Related]
20. Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma.
Lee SH; Jeung IC; Park TW; Lee K; Lee DG; Cho YL; Lee TS; Na HJ; Park YJ; Lee HG; Jeong MS; Bae KH; Lee SC; Lee HJ; Kwon YG; Hong HJ; Kim JS; Min JK
Oncotarget; 2015 Mar; 6(9):7182-94. PubMed ID: 25762629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
